Success Metrics

Clinical Success Rate
100.0%

Based on 6 completed trials

Completion Rate
100%(6/6)
Active Trials
0(0%)
Results Posted
83%(5 trials)

Phase Distribution

Ph not_applicable
1
14%
Ph phase_3
1
14%
Ph phase_2
5
71%

Phase Distribution

0

Early Stage

5

Mid Stage

1

Late Stage

Phase Distribution7 total trials
Phase 2Efficacy & side effects
5(71.4%)
Phase 3Large-scale testing
1(14.3%)
N/ANon-phased studies
1(14.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

6 of 6 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

7

all time

Status Distribution
Active(1)
Completed(6)

Detailed Status

Completed6
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
7
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 25 (71.4%)
Phase 31 (14.3%)
N/A1 (14.3%)

Trials by Status

not_yet_recruiting114%
completed686%

Recent Activity

0 active trials
Showing 5 of 7
not_yet_recruitingphase_2

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

NCT06854276
completedphase_2

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

NCT03457701
completedphase_3

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

NCT02879305
completedphase_2

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

NCT01977573
completedphase_2

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

NCT01977482
View all 7 trials

Clinical Trials (7)

Showing 7 of 7 trials
NCT06854276Phase 2

Study of SSS06 for Chemotherapy-Induced Anemia in Non-Myeloid Malignancies

Not Yet Recruiting
NCT03457701Phase 2

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Completed
NCT02879305Phase 3

Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D)

Completed
NCT01977573Phase 2

A Study to Evaluate Safety and Efficacy of GSK1278863 in Non-Dialysis Dependent (NDD) Subjects With Anemia Associated With Chronic Kidney Diseases (CKD)

Completed
NCT01977482Phase 2

Evaluation of Dose Response Relationship, Safety and Efficacy of GSK1278863 in Hemodialysis-dependent Subjects With Chronic Kidney Disease Associated Anemia

Completed
NCT01587924Phase 2

4 Week Switch Study in Hemodialysis-dependent Subjects With Anemia Associated With Chronic Kidney Disease

Completed
NCT00939978Not Applicable

Effect of Preoperative Recombinant Human Erythropoietin on Transfusion Risk in Valvular Heart Surgery

Completed

All 7 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
7